Manual clinical data abstraction is a prime target for AI automation, and Carta Healthcare is looking to hit the center of the bullseye after raising $18.25M of Series B1 funding.
Carta’s data abstraction platform leverages AI and a team of expert abstractors to automate the collection of clinical data and surface actionable insights.
- The platform converts both structured and unstructured data into standardized datasets, giving healthcare orgs a foundation of high-quality data to build on.
Although AI’s potential in the data abstraction arena has attracted an army of new competitors, Carta’s been duking it out against manual workflows since 2017.
- That gave it a big head start to refine its tech and build trust with partners, many of which participated in the round, including MemorialCare, Memorial Hermann, and MGB.
- Carta plans to put the new capital toward expanding its customer footprint, particularly in the life sciences market where it can help match patients to clinical trials using AI it acquired from Realyze.
The Takeaway
Traditional methods of data abstraction are about as labor-intensive and time-consuming as you can imagine, which makes them ideal targets for AI solutions and startups like Carta that are bringing them to market.
We’re testing a new format today – let us know if you prefer two shorter Top Stories or one longer Top Story with this quick survey!
